Lord, Abbett & Co. LLC 89bio, Inc. Transaction History

Lord, Abbett & Co. LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 07, 2024	SELL	$15.06 - $19.41 $6.01 Million - $7.75 Million	-399,376 Reduced 47.68%	438,266 $6.77 Million
Q3 2023 Nov 13, 2023	SELL	$15.06 - $19.41 $6.01 Million - $7.75 Million	-399,376 Reduced 47.68%	438,266 $6.77 Million
Q2 2023 Oct 07, 2024	BUY	$14.15 - $22.03 $1.23 Million - $1.92 Million	87,030 Added 11.59%	837,642 $15.9 Million
Q2 2023 Aug 14, 2023	BUY	$14.15 - $22.03 $1.23 Million - $1.92 Million	87,030 Added 11.59%	837,642 $15.9 Million
Q1 2023 Oct 07, 2024	BUY	$10.48 - $16.94 $7.87 Million - $12.7 Million	750,612 New	750,612 $11.4 Million
Q1 2023 May 12, 2023	BUY	$10.48 - $16.94 $7.87 Million - $12.7 Million	750,612 New	750,612 $11.4 Million

167

109M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $532M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.